EMILY ANDREW: Open Payments
NPI 1861961369 · ALPINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,419 in 60 payments from 14 companies in 2025. Trend: 2023 $1,361 · 2024 $1,703 · 2025 $1,419
Food & beverage: $1,419
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $315 |
| Madrigal Pharmaceuticals | 6 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $180 |
| Janssen Biotech, Inc. | 8 | $180 |
| GENZYME CORPORATION | 4 | $165 |
| Celltrion USA Inc. | 5 | $99 |
| Lilly USA, LLC | 2 | $52 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $49 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| QOL Medical, LLC | 2 | $35 |
Products named: REZDIFFRA, DUPIXENT, TREMFYA, ENTYVIO, RINVOQ, VEGZELMA, EOHILIA, LINZESS.
Industry payments across CA — which companies pay providers there.
